Market Access

Having recognized biopharma’s great potential in effectively treating rare, chronic and severe diseases, our mission has been to ensure that patients in the countries we operate have direct access to innovative biopharma therapies.

Market Access activities for the territory covered by GENESIS Pharma, which consists of 7 EU and 5 non-EU countries, are coordinated by our Governmental Affairs team. Over the years, this highly experienced team has successfully accomplished the pricing and reimbursement of numerous high-value and orphan medicines -under various frameworks including reference-based pricing, HTA, tenders, managed entry agreements - and is always looking for ways to optimize the added value of innovation. Part of the market access strategy we employ is  also the implementation, in collaboration with our Partners, of Early Access Programs that address the needs of patients earlier.